hydroxychloroquine sulfate accord 200 mg tabletki powlekane
accord healthcare polska sp. z o.o. - hydroxychloroquini sulphas - tabletki powlekane - 200 mg
magnesium sulfate kalceks 200 mg/ml roztwór do wstrzykiwań / do infuzji
as kalceks - magnesii sulfas heptahydricus - roztwór do wstrzykiwań / do infuzji - 200 mg/ml
protamine sulfate leo pharma 14000 iu/ml roztwór do wstrzykiwań / do infuzji
leo pharma a/s - protamini sulfas - roztwór do wstrzykiwań / do infuzji - 14000 iu/ml
zeposia
bristol-myers squibb pharma eeig - ozanimod chlorowodorek - multiple sclerosis, relapsing-remitting; colitis, ulcerative - leki immunosupresyjne - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
hydroxychloroquine sulfate edest 200 mg tabletki powlekane
intas third party sales 2005 s.l. - hydroxychloroquini sulphas - tabletki powlekane - 200 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
briumvi
neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.
metaxol (20 mg + 100 mg)/ml roztwór do podania w wodzie do picia
eurovet animal health b.v. - trimethoprimum + sulfametoksazol - roztwór do podania w wodzie do picia - (20 mg + 100 mg)/ml - kura; świnia
beriplex p/n 1000 1000 j.m. proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
csl behring gmbh - prothrombinum multiplex humanum - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 1000 j.m.